Biomea Fusion, Inc. (BMEA)
0.8364
0.00 (0.00%)
USD |
NASDAQ |
Oct 15, 16:00
0.855
+0.02
(+2.22%)
After-Hours: 20:00
Biomea Fusion Cash from Operations (TTM) : -47.06M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -47.06M |
| March 31, 2026 | -56.37M |
| December 31, 2025 | -70.37M |
| September 30, 2025 | -87.19M |
| June 30, 2025 | -100.22M |
| March 31, 2025 | -113.54M |
| December 31, 2024 | -119.89M |
| September 30, 2024 | -112.73M |
| June 30, 2024 | -111.41M |
| March 31, 2024 | -104.58M |
| December 31, 2023 | -96.59M |
| September 30, 2023 | -93.96M |
| Date | Value |
|---|---|
| June 30, 2023 | -86.85M |
| March 31, 2023 | -76.47M |
| December 31, 2022 | -62.42M |
| September 30, 2022 | -58.12M |
| June 30, 2022 | -50.31M |
| March 31, 2022 | -41.36M |
| December 31, 2021 | -35.44M |
| September 30, 2021 | -22.28M |
| June 30, 2021 | -14.39M |
| March 31, 2021 | -8.282M |
| December 31, 2020 | -4.459M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| REGENXBIO, Inc. | -246.67M |
| Compass Therapeutics, Inc. | -56.11M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |